Iida S - Search Results

1

An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.

Nihira K, Miki Y, Iida S, Narumi S, Ono K, Iwabuchi E, Ise K, Mori K, Saito M, Ebina M, Sato I, Maemondo M, Yamada-Okabe H, Kondo T, Sasano H. Nihira K, et al. Among authors: iida s. J Pathol. 2014 Oct;234(2):277-88. doi: 10.1002/path.4354. Epub 2014 Aug 18. J Pathol. 2014. PMID: 24687913

2

Activation of AXL and antitumor effects of a monoclonal antibody to AXL in lung adenocarcinoma.

Iida S, Miki Y, Suzuki T, Mori K, Saito M, Niikawa H, Kondo T, Yamada-Okabe H, Sasano H. Iida S, et al. Anticancer Res. 2014 Apr;34(4):1821-7. Anticancer Res. 2014. PMID: 24692715

3

Novel classification based on immunohistochemistry combined with hierarchical clustering analysis in non-functioning neuroendocrine tumor patients.

Iida S, Miki Y, Ono K, Akahira J, Suzuki T, Ishida K, Watanabe M, Sasano H. Iida S, et al. Cancer Sci. 2010 Oct;101(10):2278-85. doi: 10.1111/j.1349-7006.2010.01657.x. Epub 2010 Aug 2. Cancer Sci. 2010. PMID: 20682006 Free PMC article.

4

Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment.

Miki Y, Suzuki T, Abe K, Suzuki S, Niikawa H, Iida S, Hata S, Akahira J, Mori K, Evans DB, Kondo T, Yamada-Okabe H, Sasano H. Miki Y, et al. Among authors: iida s. Cancer Res. 2010 Aug 15;70(16):6659-69. doi: 10.1158/0008-5472.CAN-09-4653. Cancer Res. 2010. PMID: 20710045

5

Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.

Iida S, Miki Y, Ono K, Akahira J, Nakamura Y, Suzuki T, Sasano H. Iida S, et al. Mol Cell Endocrinol. 2012 Mar 5;350(1):99-106. doi: 10.1016/j.mce.2011.11.024. Epub 2011 Dec 8. Mol Cell Endocrinol. 2012. PMID: 22178087

6

[Immunohistochemical evaluation of somatostatin receptor subtypes in surgical pathology specimens of neuroendocrine tumors].

Sasano H, Iida S, Kasajima A. Sasano H, et al. Among authors: iida s. Pathologe. 2010 Oct;31 Suppl 2:199-203. doi: 10.1007/s00292-010-1369-z. Pathologe. 2010. PMID: 20812014 German.

7

Aryl hydrocarbon receptor in breast cancer—a newly defined prognostic marker.

Saito R, Miki Y, Hata S, Takagi K, Iida S, Oba Y, Ono K, Ishida T, Suzuki T, Ohuchi N, Sasano H. Saito R, et al. Among authors: iida s. Horm Cancer. 2014 Feb;5(1):11-21. doi: 10.1007/s12672-013-0160-z. Horm Cancer. 2014. PMID: 24078229 Free PMC article.

8

Tips for percutaneous nephrolithotomy for transplant kidney stone.

Yagisawa T, Shimizu T, Tachiki A, Ishiyama Y, Onohara T, Iida S, Ishida H, Takagi T. Yagisawa T, et al. Among authors: iida s. IJU Case Rep. 2024 Oct 13;8(1):32-35. doi: 10.1002/iju5.12800. eCollection 2025 Jan. IJU Case Rep. 2024. PMID: 39749290 Free PMC article.

9

Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan.

Tagami N, Uchiyama M, Suzuki K, Shirai H, Seto T, Iida S. Tagami N, et al. Among authors: iida s. Int J Hematol. 2024 Dec 27. doi: 10.1007/s12185-024-03904-y. Online ahead of print. Int J Hematol. 2024. PMID: 39729222

10

DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma.

Sunami K, Iida S, Tsukada N, Fujii T, Kato H, Fukushima R, Wakabayashi S, Nakano H, Roy-Ghanta S, Kremer BE. Sunami K, et al. Among authors: iida s. Int J Hematol. 2024 Dec 24. doi: 10.1007/s12185-024-03889-8. Online ahead of print. Int J Hematol. 2024. PMID: 39718747

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,699 results

Search Page

Filters